Smithfield Trust Co. Acquires 409 Shares of Humana Inc (HUM)

Share on StockTwits

Smithfield Trust Co. increased its position in shares of Humana Inc (NYSE:HUM) by 531.2% in the third quarter, Holdings Channel reports. The institutional investor owned 486 shares of the insurance provider’s stock after buying an additional 409 shares during the period. Smithfield Trust Co.’s holdings in Humana were worth $165,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HUM. FMR LLC raised its stake in Humana by 12.7% during the second quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock worth $3,634,811,000 after buying an additional 1,374,030 shares during the last quarter. Glenmede Trust Co. NA raised its stake in Humana by 153.7% during the second quarter. Glenmede Trust Co. NA now owns 500,266 shares of the insurance provider’s stock worth $148,895,000 after buying an additional 303,080 shares during the last quarter. Unigestion Holding SA bought a new position in Humana during the second quarter worth $79,340,000. LFA Lugano Financial Advisors SA bought a new position in Humana during the second quarter worth $204,000. Finally, Bank of Montreal Can raised its stake in Humana by 61.7% during the second quarter. Bank of Montreal Can now owns 413,429 shares of the insurance provider’s stock worth $123,049,000 after buying an additional 157,752 shares during the last quarter. 92.62% of the stock is owned by institutional investors and hedge funds.

HUM opened at $338.95 on Friday. Humana Inc has a 1-year low of $231.90 and a 1-year high of $355.88. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $48.77 billion, a price-to-earnings ratio of 25.36, a P/E/G ratio of 1.73 and a beta of 1.03.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating the consensus estimate of $4.29 by $0.29. Humana had a net margin of 2.70% and a return on equity of 19.36%. The firm had revenue of $14.21 billion during the quarter, compared to the consensus estimate of $13.97 billion. During the same period in the previous year, the firm posted $3.39 earnings per share. On average, equities analysts predict that Humana Inc will post 14.44 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.59%. The ex-dividend date is Friday, December 28th. Humana’s dividend payout ratio (DPR) is currently 17.08%.

A number of equities analysts recently weighed in on HUM shares. Royal Bank of Canada reissued a “hold” rating and set a $318.00 target price on shares of Humana in a research note on Thursday, August 2nd. Jefferies Financial Group lifted their target price on shares of Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Morgan Stanley lifted their target price on shares of Humana from $362.00 to $365.00 and gave the stock an “overweight” rating in a research note on Thursday, August 2nd. Bank of America lifted their target price on shares of Humana from $338.00 to $375.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $355.00 target price on shares of Humana in a research note on Thursday, August 2nd. Seven analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $352.30.

In other news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the sale, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the sale, the insider now directly owns 14,289 shares of the company’s stock, valued at $4,715,370. The disclosure for this sale can be found here. Insiders own 0.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Smithfield Trust Co. Acquires 409 Shares of Humana Inc (HUM)” was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://weekherald.com/2018/11/10/smithfield-trust-co-acquires-409-shares-of-humana-inc-hum.html.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Featured Article: NASDAQ

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply